US sets zero tariff on certain speciality drugs, ingredients from India, 19 other nations
US Creates Zero-Tariff Channel for Select Specialty Medicines From India and Other Partners
Bharatmorningnews.com – The United States has opened a zero-tariff route for selected specialty medicines and pharmaceutical inputs imported from India and 19 other countries. The measure covers treatments and ingredients linked to rare conditions and advanced therapies, while a separate 100 per cent duty on specified patented pharmaceutical products is set to apply more broadly from September 29.
The policy forms part of the implementation of President Donald Trump’s plan to adjust duties on pharmaceutical imports. The US Commerce Department has published the list of eligible countries in the Federal Register, setting out which imports may enter at a zero ad valorem tariff rate.
For pharmaceutical companies, suppliers and patients, the distinction is significant. The zero-duty provision applies to specialised products that can be central to complex treatment pathways, while generic medicines remain outside the Section 232 pharmaceutical tariff regime.
Which medicines and ingredients qualify?
The eligible category includes medicines designated for rare diseases, treatments connected with infertility, cell therapies, gene therapies and antibody-drug conjugates, commonly known as ADCs. Animal pharmaceutical products are also included within the covered group.
The benefit is not limited to finished medicines. Components used in producing qualifying products can also receive the zero per cent tariff treatment. This may matter for supply chains involving active ingredients, key starting materials and specialised manufacturing inputs that move across several countries before a medicine reaches the US market.
An ad valorem tariff is charged as a fixed percentage of a product’s monetary value. Setting that rate at zero means the eligible imports will not face such a customs duty when entering the United States.
India among 20 eligible countries
India is included in the group covered by the zero-tariff provision. The other eligible jurisdictions are Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, Indonesia, Japan, Jordan, Malaysia, North Macedonia, South Korea, Switzerland, Liechtenstein, Taiwan, Thailand, Britain and Vietnam.
Products from these countries can receive the exemption because they have an existing or anticipated trade and security framework agreement with the United States. The country list places India alongside a mix of major pharmaceutical markets, manufacturing hubs and trade partners involved in international medicine supply networks.
The framework is especially relevant because pharmaceutical production often relies on specialised cross-border sourcing. A finished treatment may require active ingredients, biological materials, packaging components or other technical inputs supplied from different locations. The zero-rate treatment for covered goods and components is designed to preserve access to certain specialty products despite the broader tariff programme.
Separate 100 per cent duty on specified patented products
The exemption exists alongside a much tougher tariff measure for certain patented pharmaceuticals, biologics and related ingredients. A proclamation issued on April 2 imposed a 100 per cent tariff on specified imports in those categories as part of an effort to encourage pharmaceutical production within the United States.
That proclamation took effect on July 31 for companies identified in one annex. It will extend to other covered companies on September 29. The latest Commerce Department notice clarifies the boundaries of the policy by identifying products that can still qualify for a zero tariff.
Generic pharmaceutical products and their related ingredients are not subject to the Section 232 pharmaceutical tariffs. This distinction separates widely used off-patent medicines from the patented products and biologics targeted under the tariff action.
The structure creates different treatment for different parts of the market. Covered patented products may face a substantial duty, selected specialty therapies from eligible partners can enter duty-free, and generic medicines remain excluded from the Section 232 pharmaceutical tariff programme.
Technical updates to the original proclamation
The Commerce Department notice also includes technical changes to the April proclamation. One amendment makes clear that “generic pharmaceutical articles” specifically include unpatented animal health products. The adjustment brings certain veterinary medicines within the definition used for the tariff rules.
Another clarification narrows the meaning of “pharmaceutical articles.” Under the updated language, the term covers finished pharmaceutical products, their active pharmaceutical ingredients and the key starting materials used for those ingredients. The clarification is intended to define more precisely which goods are within the policy’s scope.
These details are important for manufacturers and importers assessing whether a product is covered. Pharmaceutical goods can be categorised by patent status, treatment type, manufacturing stage and the role an ingredient plays in a finished medicine. The updated definitions aim to reduce uncertainty when determining tariff treatment.
What the policy means for specialty drug supply
The zero-tariff list highlights the US effort to balance domestic manufacturing goals with continued access to specialised therapies and the materials needed to make them. Treatments for rare diseases, advanced cell and gene therapies, and antibody-drug conjugates are often highly technical products with distinct sourcing and production requirements.
For India, inclusion in the eligible group gives exporters of qualifying specialty medicines and inputs a potential tariff advantage in the US market. It also underscores the importance of trade and security arrangements in determining which pharmaceutical imports receive preferential treatment.
The measure does not remove the wider tariff pressure facing all pharmaceutical categories. Instead, it establishes a defined exemption for selected goods from particular countries while maintaining the planned 100 per cent duty on specified patented pharmaceuticals and associated ingredients. Companies importing covered products will need to assess both the nature of the medicine and the origin of the shipment when applying the rules.
Related Reading
Frequently Asked Questions
What is US sets zero tariff on certain?US sets zero tariff on certain is the main topic of this guide. The article explains the context, practical details, and next steps readers should understand.
Why does US sets zero tariff on certain matter?US sets zero tariff on certain matters because readers are looking for a useful answer, not just a short summary. Good content should match search intent and help them decide what to do next.